Musa Tariq Biography and Net Worth

Director of Guardant Health

Musa Tariqhas served as a member of Guardant Health’s board of directors since March 2023. Mr. Tariq most recently served as Chief Marketing Officer of GoFundMe, a crowdfunding platform, from January 2021 to June 2023. He joined GoFundMe to further build the GoFundMe brand and drive the company’s marketing and communications functions. Prior to GoFundMe, Mr. Tariq was Global Head of Marketing for Airbnb Experiences, a division of Airbnb, Inc., from September 2018 to December 2020 where he drove brand awareness and adoption of that rapidly growing part of Airbnb’s business. Before Airbnb, he was Chief Brand Officer at Ford Motor Company from January 2017 to March 2018. Mr. Tariq has also held marketing leadership roles at Apple, Nike and Burberry.

Mr. Tariq has a Bachelor of Science degree in geography and economics from London School of Economics. A distinguished counselor to iconic and emerging global brands, Mr. Tariq currently serves as an advisor to MasterClass, The British Fashion Council, Felix Capital and several other startups.

What is Musa Tariq's net worth?: The estimated net worth of Musa Tariq is at least $147,192.24 as of March 19th, 2025. Mr. Tariq owns 3,211 shares of Guardant Health stock worth more than $147,192 as of March 26th. This net worth estimate does not reflect any other assets that Mr. Tariq may own. Learn More about Musa Tariq's net worth.
How do I contact Musa Tariq?: The corporate mailing address for Mr. Tariq and other Guardant Health executives is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. Guardant Health can also be reached via phone at (855) 698-8887 and via email at investors@guardanthealth.com. Learn More on Musa Tariq's contact information.
Has Musa Tariq been buying or selling shares of Guardant Health?: Over the course of the past ninety days, Musa Tariq has sold $15,034.76 in Guardant Health stock. Most recently, Musa Tariq sold 116 shares of the business's stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $43.70, for a transaction totalling $5,069.20. Following the completion of the sale, the director now directly owns 3,211 shares of the company's stock, valued at $140,320.70. Learn More on Musa Tariq's trading history.
Who are Guardant Health's active insiders?: Guardant Health's insider roster includes Derek Bertocci (CFO), Ian Clark (Director), Helmy Eltoukhy (CEO), Meghan Joyce (Director), Kumud Kalia (Insider), Samir Kaul (Director), Stanley Meresman (Director), Amelia Merrill (SVP), Amirali Talasaz (COO), and Musa Tariq (Director). Learn More on Guardant Health's active insiders.
Are insiders buying or selling shares of Guardant Health?: During the last year, insiders at the sold shares 8 times. They sold a total of 5,880 shares worth more than $193,244.76. The most recent insider tranaction occured on March, 19th when Director Musa Tariq sold 116 shares worth more than $5,069.20. Insiders at Guardant Health own 5.5% of the company. Learn More about insider trades at Guardant Health.
Information on this page was last updated on 3/19/2025.

Musa Tariq Insider Trading History at Guardant Health

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/19/2025	Sell	116	$43.70	$5,069.20	3,211
2/20/2025	Sell	116	$48.33	$5,606.28	3,078
1/17/2025	Sell	116	$37.58	$4,359.28	2,944
12/18/2024	Sell	116	$34.85	$4,042.60	2,810
12/13/2024	Sell	2,320	$35.00	$81,200.00	2,676

Musa Tariq Buying and Selling Activity at Guardant Health

Guardant Health Company Overview

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Today's Range

Now: $45.84

$45.47

$47.68

50 Day Range

MA: $44.37

$35.84

$49.94

2 Week Range

Now: $45.84

$15.81

$50.89

Volume

1,462,076 shs

Average Volume

2,142,323 shs

Market Capitalization

$5.66 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.5